SCENESSE® (afamelanotide)

About Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals is a mission-driven company focused on developing and commercializing treatments for severe, often rare, disorders of the skin and brain with no alternative therapies. Its core achievement is the global approval and commercialization of SCENESSE® (afamelanotide) for erythropoietic protoporphyria (EPP), establishing it as a leader in photomedicine. The company's strategy leverages this foundational melanocortin platform to expand into adjacent indications like vitiligo and stroke, while simultaneously commercializing a luxury PhotoCosmetics division to diversify revenue and fund R&D.

About Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals is a mission-driven company focused on developing and commercializing treatments for severe, often rare, disorders of the skin and brain with no alternative therapies. Its core achievement is the global approval and commercialization of SCENESSE® (afamelanotide) for erythropoietic protoporphyria (EPP), establishing it as a leader in photomedicine. The company's strategy leverages this foundational melanocortin platform to expand into adjacent indications like vitiligo and stroke, while simultaneously commercializing a luxury PhotoCosmetics division to diversify revenue and fund R&D.

About Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals is a mission-driven company focused on developing and commercializing treatments for severe, often rare, disorders of the skin and brain with no alternative therapies. Its core achievement is the global approval and commercialization of SCENESSE® (afamelanotide) for erythropoietic protoporphyria (EPP), establishing it as a leader in photomedicine. The company's strategy leverages this foundational melanocortin platform to expand into adjacent indications like vitiligo and stroke, while simultaneously commercializing a luxury PhotoCosmetics division to diversify revenue and fund R&D.

About Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals is a mission-driven company focused on developing and commercializing treatments for severe, often rare, disorders of the skin and brain with no alternative therapies. Its core achievement is the global approval and commercialization of SCENESSE® (afamelanotide) for erythropoietic protoporphyria (EPP), establishing it as a leader in photomedicine. The company's strategy leverages this foundational melanocortin platform to expand into adjacent indications like vitiligo and stroke, while simultaneously commercializing a luxury PhotoCosmetics division to diversify revenue and fund R&D.

About Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals is a mission-driven company focused on developing and commercializing treatments for severe, often rare, disorders of the skin and brain with no alternative therapies. Its core achievement is the global approval and commercialization of SCENESSE® (afamelanotide) for erythropoietic protoporphyria (EPP), establishing it as a leader in photomedicine. The company's strategy leverages this foundational melanocortin platform to expand into adjacent indications like vitiligo and stroke, while simultaneously commercializing a luxury PhotoCosmetics division to diversify revenue and fund R&D.

Therapeutic Areas